The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
Matteo DugoChiun-Sheng HuangDaniel EgleBegoña BermejoClaudio ZamagniRobert S SeitzTyler J NielsenMarc ThillAntonio Antón-TorresStefania RussoEva Ciruelos GilBrock L SchweitzerDouglas Teller RossBarbara GalbardiRichard GreilVladimir SemiglazovGyorffy BalazsMarco ColleoniCatherine M KellyGabriella MarianiLucia Del MastroOlivia BlasiMaurizio CallariLajos PusztaiPinuccia ValagussaGiuseppe VialeLuca GianniGiampaolo BianchiniPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
DetermaIO identified patients who benefited from neoadjuvant immunotherapy resulting in improved pCR rate, independently of PDL1.